Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Refractory Cirrhotic Ascites
NCT06919523Phase 2Not yet recruiting
- Sponsor
- Mansoura University
- Start
- Apr 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of dapagliflozin in ascites (2 arms), sponsored by Mansoura University. Primary endpoint: Difference in ascites control between the two groups at the end of treatment at 3 months. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
ascites
Beyond the preview
Go deeper on NCT06919523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919523.